Practice Finance

Inflation is tops but health care concern is high as pessimism spreads like wildfire.

Faster prior auths are a priority for physicians and patients, so the new rules will help family doctors.

MGMA outlines legal technicality that HHS needs to address if Congress takes action.

January meeting opens new year of wrangling in Washington as doctor costs go up and payments go down.

Federal figures include health care services and commodities.

CMS announces figures blowing by last year’s record of 16.3 million enrollees.

Americans pay more, but that could change when Medicare begins negotiating prices.

AMGA weighs in on policy changes proposed for 2025.

The top news stories in primary care today.

Internal medicine physicians ‘concerned’ about patients ordering prescription drugs directly from pharmaceutical makers.

President, GOP clash over meanings of economic indicators.

‘Overly punitive’ approach will discourage move to value-based care.

If you practice here, your patients are getting a bargain.

Report to Congress details expected recoveries, questioned costs, and potential savings.

Young doctors’ early decisions can have profound effects on professional development and retirement. Here are some questions to consider.

Here’s the cost of getting into the exam room.

HHS, DOJ say COVID-19 was a factor in enforcement during report time period.

Federal analysts project 19 million people covered by January 2024 deadline.

Proposals, money and 'perpetual hope' are all there. Now action is needed.

AMA examines how dominating metro areas has effects on patients and physicians.

Physicians, hospitals, prescription drugs at top of list for expenditures.

The top news stories in primary care today.

Costs for shelter and medical care rose but were offset by falling energy prices

House approves landmark ‘Lower Costs, More Transparency Act.’

Health insurance giant Cigna announces $10B stock buyback.

Law could change Medicare Physician Fee Schedule, affecting reimbursement to doctors.

Federal figures show growth across some industries and declines in others.

Public-private partnerships will crumble, hurting drug innovation and eventually patients, Republicans say.

December meeting has two days of discussion planned.

‘The results are alarming,’ with potential financial effects for patients and pharmacies, researchers say.